There is an increasing proportion of HIV-positive patients exposed to all licensed classes of antiretrovirals, and the response to salvage regimens may be poor. Among over 8500 patients in EuroSIDA, the proportion of treated patients exposed to nucleosides, protease inhibitors (PIs) and non-nucleoside reverse transcriptase inhibitor (NNRTI) increased from 0% in 1996 to 47% in 2001. Four-hundred-and-thirteen patients, who had failed virologically two highly active antiretroviral therapy (HAART) regimens and experienced all three main drug classes, started a salvage regimen of at least three drugs, in which at least one new PI or NNRTI was included. Median viral load was 4.7 log copies/ml [Interquartile range (IQR) 4.2–5.2], CD4 lymphocyte count 150/mm3 (IQR 60–274/mm3) and follow-up 14 months. Of these patients, 283 (69%) subsequently experienced at least a 1 log decline in viral load and 202 (49%) achieved a viral load <500 copies/ml. Conversely, the CD4 count halved from the baseline value in 88 (21%), and 45 (11%) experienced a new AIDS-defining disease. In multivariable analyses, a 1 log viral load reduction was related to baseline viral load [relative hazard (RH) 1.27 per 1 log higher; P=0.008], a previous viral load of less than 500 copies/ml (RH 1.69; P=0.002), more recent initiation of the regimen (RH 1.36 per year more recent; P=0.02), number of new drugs in the regimen (RH 1.20 per drug; P=0.02), time since start of antiretroviral therapy (RH 0.94 per extra year; P=0.035) and time spent on HAART with viral load >1000 copies/ml (RH 0.96 per extra month; P=0.0001). Analysis of factors associated with CD4 count decline and new AIDS disease also indicated improved outcomes in more recent times and a tendency for a better response in those starting more new drugs, but no relationship with the total number of drugs. Outcomes in people starting salvage regimens appear to depend on the number of new drugs started but not on the total number of drugs being used.
References
1.
HammerS.M., SquiresK.E., HughesM.D., GrimesJ.M., DemeterL.M., CurrierJ.S., EronJ.J.Jr., FeinbergJ.E., BalfourH.H.Jr., DeytonL.R., ChodakewitzJ.A., & FischlM.A.A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team [see comments]. New England Journal of Medicine1997; 337: 725–733.
2.
GulickR.M., MellorsJ.W., HavlirD., EronJ.J., GonzalezC., McMahonD., RichmanD.D., ValentineF.T., JonasL., MeibohmA., EminiE.A., & ChodakewitzJ.A.Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior anti-retroviral therapy. New England Journal of Medicine1997; 337: 734–739.
3.
MoutonY., AlfandariS., ValetteM., CartierF., DellamonicaP., HumbertG., LangJ.M., MassipP., MechaliD., LeclercqP., ModaiJ., & PortierH.Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Federation National des Centres de Lutte contre le SIDA. AIDS1997; 11: F101–F105.
4.
MocroftA., KatlamaC., JohnsonA.M., PradierC., AntunesF., MulcahyF., ChiesiA., PhillipsA.N., KirkO., & LundgrenJ.D.AIDS across Europe, 1994–98: the EuroSIDA study. Lancet2000; 356: 291–296.
5.
PalellaF.J.Jr., DelaneyK.M., MoormanA.C., LovelessM.O., FuhrerJ., SattenG.A., AschmanD.J., & HolmbergS.D.Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. New England Journal of Medicine1998; 338: 853–860.
6.
MocroftA., VellaS., BenfieldT.L., ChiesiA., MillerV., GargalianosP., d'ArminioM.A., YustI., BruunJ.N., PhillipsA.N., & LundgrenJ.D.Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet1998; 352: 1725–1730.
7.
EggerM., HirschelB., FrancioliP., SudreP., WirzM., FleppM., RickenbachM., MalinverniR., VernazzaP., & BattegayM.Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. British Medical Journal1997; 315: 1194–1199.
8.
ParedesR., MocroftA., KirkO., LazzarinA., BartonS.E., van LunzenJ., KatzensteinT.L., AntunesF., LundgrenJ.D., & ClotetB.Predictors of virological success and ensuing failure in HIV-positive patients starting highly active anti-retroviral therapy in Europe: results from the EuroSIDA study. Archives of Internal Medicine2000; 160: 1123–1132.
9.
LedergerberB., EggerM., OpravilM., TelentiA., HirschelB., BattegayM., VernazzaP., SudreP., FleppM., FurrerH., FrancioliP., & WeberR.Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet1999; 353: 863–868.
10.
StaszewskiS., MillerV., SabinC., CarlebachA., BergerA.M., WeidmannE., HelmE.B., HillA., & PhillipsA.Virological response to protease inhibitor therapy in an HIV clinic cohort. AIDS1999; 13: 367–373.
11.
FatkenheuerG., HoetelmansR.M., HunnN., SchwenkA., FranzenC., ReiserM., JutteA., RockstrohJ., DiehlV., & SalzbergerB.Salvage therapy with regimens containing ritonavir and saquinavir in extensively pretreated HIV-infected patients. AIDS1999; 13: 1485–1489.
12.
DeeksS.G., GrantR.M., BeattyG.W., HortonC., DetmerJ., & EastmanS.Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure. AIDS1998; 12: F97–F102.
13.
DeeksS.G., HechtF.M., SwansonM., ElbeikT., LoftusR., CohenP.T., & GrantR.M.HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS1999; 13: F35–F43.
14.
DeeksS.G., HellmannN.S., GrantR.M., ParkinN.T., PetropoulosC.J., BeckerM., SymondsW., ChesneyM., & VolberdingP.A.Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. Journal of Infectious Diseases1999; 179: 1375–1381.
15.
HallC.S., RainesC.P., BarnettS.H., MooreR.D., & GallantJ.E.Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens. AIDS1999; 13: 1207–1212.
16.
KhannaN., KlimkaitT., SchifferV., IrigoyenJ., TelentiA., HirschelB., & BattegayM.Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. Swiss HIV Cohort Study. AIDS2000; 14: 791–799.
17.
PikettyC., RaceE., CastielP., BelecL., PeytavinG., Si-MohamedA., Gonzalez-CanaliG., WeissL., ClavelF., & KazatchkineM.D.Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy. AIDS1999; 13: F71–F77.
18.
MontanerJ.S., HarriganP.R., JahnkeN., RaboudJ., CastilloE., HoggR.S., YipB., HarrisM., MontessoriV., & O'ShaughnessyM.V.Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens. AIDS2001; 15: 61–69.
19.
CarpenterC.C., CooperD.A., FischlM.A., GatellJ.M., GazzardB.G., HammerS.M., HirschM.S., JacobsenD.M., KatzensteinD.A., MontanerJ.S., RichmanD.D., SaagM.S., SchechterM., SchooleyR.T., ThompsonM.A., VellaS., YeniP.G., & VolberdingP.A.Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. Journal of the American Medical Association2000; 283: 381–390.
20.
MillerV., GuteP., CarlebachA., NisiusG., LederT., & RottmannC.Baseline resistance and virological response to Mega-HAART salvage therapies.6th Conference on Retroviruses and Opportunistic Infections. Chicago, USA, 31 January–4 February 1999; Abstract 130.
21.
YouleM., MocroftA., JohnsonM., TyrerM., DevereuxH., & LovedayC.Surrogate marker responses to multidrug combinations comprising hydroxyurea, efavirenz, double protease inhibitors, and nucleoside analogs in protease inhibitor failures.39th ICAAC, San Francisco, USA, 26–29 September 1999, Abstract 2207.
22.
LundgrenJ.D., PhillipsA.N., VellaS., KatlamaC., LedergerberB., JohnsonA.M., ReissP., GatellJ., ClumeckN., DietrichM., BenfieldT.L., NielsenJ.O., & PedersenC.Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients. EuroSIDA Study Group. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology1997; 16: 153–160.
23.
PhillipsA.N., KatlamaC., BartonS., VellaS., BlaxhultA., ClotetB., GoebelF.D., HirschelB., PedersenC., & LundgrenJ.D.Survival in 2367 zidovudine-treated patients according to use of other nucleoside analogue drugs. The EuroSIDA Study Group. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology1998; 17: 239–244.
24.
1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.Morbidity and Mortality Weekly Report1992; 41: 1–19.
LorenziP., OpravilM., HirschelB., ChaveJ.P., FurrerH.J., SaxH., PernegerT.V., PerrinL., KaiserL., & YerlyS.Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study. AIDS1999; 13: F17–F21.
27.
HavlirD.V., HellmannN.S., PetropoulosC.J., WhitcombJ.M., CollierA.C., HirschM.S., TebasP., SommadossiJ.P., & RichmanD.D.Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. Journal of the American Medical Association2000; 283: 229–234.
28.
DescampsD., FlandreP., CalvezV., PeytavinG., MeiffredyV., CollinG., DelaugerreC., Robert-DelmasS., BazinB., AboulkerJ.P., PialouxG., RaffiF., & Brun-VezinetF.Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team. Journal of the American Medical Association2000; 283: 205–211.
29.
HirschM.S., Brun-VezinetF., D'AquilaR.T., HammerS.M., JohnsonV.A., KuritzkesD.R., LovedayC., MellorsJ.W., ClotetB., ConwayB., DemeterL.M., VellaS., JacobsenD.M., & RichmanD.D.Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel [see comments]. Journal of the American Medical Association2000; 283: 2417–2426.
30.
Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting.The EuroGuidelines Group for HIV resistanceAIDS2001; 15: 309–320.
31.
MeynardJ., VrayM., Morand-JoubertL., MatheronS., PeytavinG., ClavelF., Brun-VezinetF., & GirardP.M.Impact of treatment guided by phenotypic or genotypic resistance tests on the response to antiretroviral therapy: a randomized trial (NARVAL, ANRS 088). Antiviral Therapy2000; 5 (Suppl. 3): 67–68.
32.
CohenC., KesslerH., HuntS., SensionS., FarthingC., ConantM., JacobsonS., NadlerJ., VerbiestW., HertogsK., AmesM., RinehartA., & GrahamN.Phenotypic resistance testing significantly improves response to therapy: final analysis of a randomized trial (VIRA3001). Antiviral Therapy2000; 5 (Suppl. 3): 67.
33.
BaxterJ.D., MayersD.L., WentworthD.N., NeatonJ.D., HooverM.L., WintersM.A., MannheimerS.B., ThompsonM.A., AbramsD.I., BrizzB.J., IoannidisJ.P., & MeriganT.C.A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS2000; 14: F83–F93.
LundgrenJ.D., MocroftA., GatellJ.M., LedergerberB., D'Arminio MonforteA., HermansP., GoebelF-D, BlaxhultA., KirkO., & PhillipsA.N.A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: Results from the EuroSIDA study. Journal of Infectious Diseases2002; 185: 178–187.
36.
MehtaS., MooreR.D., & GrahamN.M.Potential factors affecting adherence with HIV therapy. AIDS1997; 11: 1665–1670.
37.
van RoonE.N., VerzijlJ.M., JuttmannJ.R., LenderinkA.W., BlansM.J., & EgbertsA.C.Incidence of discontinuation of highly active antiretroviral combination therapy (HAART) and its determinants. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology1999; 20: 290–294.
